Exton, United States
The innovative gel, when applied to the resected tumor cavity, is engineered to eradicate cancer cells when stimulated by a low power laser. Notably, a single dosage of GBGel has demonstrated 100% elimination of brain cancer in Wistar rats without recurrence. Moreover, preliminary toxicity studies have indicated that GBGel is well-tolerated and exhibits no observed side effects at the treatment dose.
Established in 2015, LeadInvent Pharma operates in the Health Care and Pharmaceutical industries, positioning itself as a frontrunner in the applications of nanotechnology and laser technologies for cancer treatment. With its groundbreaking approach, the company has the potential to revolutionize brain cancer treatment and significantly improve patient outcomes.
